Full-Time

Revenue Senior Accountant

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

No salary listed

Senior

Company Does Not Provide H1B Sponsorship

London, UK

Hybrid-Eligible: work remotely up to two days per week; or work five days per week on-site with ad hoc flexibility.

Category
Financial Accounting
Management Accounting
Accounting
Required Skills
Data Analysis
Requirements
  • Experience in an accounting environment with significant exposure to revenue accounting being an advantage
  • Qualified/Part Qualified Accountant (ACA/ACCA/CIMA or equivalent) is an advantage
  • Knowledge and proficiency in US GAAP revenue accounting is an advantage
  • Work experience in a service driven function with a business partnering focus within a multinational shared service/GBS organization would be an advantage
  • Communication and influencing skills in working with multiple stakeholders both internal and external
  • Professional attitude with a proactive and flexible approach
  • Adaptable to change and ability to work well under pressure, whilst maintaining attention to detail
  • Ability to manage multiple and competing priorities
  • Ability to work independently with strong attention to accuracy and detail
  • Ability to collaborate across and within different levels of the organization
Responsibilities
  • Build a partnership of trust and open communication with the Revenue Accounting Manager and Senior Manager, the International and Global Revenue Accounting teams and wider International and US corporate stakeholders
  • Perform Revenue Accounting month-end close activities, including but not limited to: Preparation of monthly gross to net revenue journal entries, Analysis of gross to net accounts, including discounts, rebates and pharma fees for multiple countries per the contractual agreements, Gross to net account resolution of variances and queries from internal stakeholders, Analysing sales forecast information to determine the best estimates of accruals for discounts, rebates and pharma fees, Prepare revenue recognition journal entries based on contractual agreement, Support the monthly flash process (early estimation of revenues), Reconciliation of gross to net revenue accounts, Review of 3PL AR reporting and reconciliation to Vertex accounting, Prepare and file pharma fee quarterly submission
  • First time accuracy and completion of month end close activities in the region to provide the finance and commercial organisation with value-add timely insight on the revenue accounting implications of new product launches, reimbursement, distribution agreements, new customer contracts and contract extensions. As well as ensuring such contracts are operationalised correctly by partnering with our 3PL management team
  • Monitoring of reimbursement agreements for appropriate revenue recognition and continued compliance with key terms, including but not limited to supporting commercial team with external reporting requirements, payback and rebate invoicing, forecast alignment
  • Preparation of: group reporting requirements for region, data analysis to support business and accounts reviews, general ledger account analysis and reconciliation of complex gross to net revenue accounts, all month end close activities for revenue accounting, including SOX compliance and controls, GL reconciliations
  • Support internal and external audit requests for SOX, group, and statutory audits
  • Provide disclosure for SEC quarterly and annual reporting in HFM
  • Drive change across the team, bring experience of simplification and continuous improvement mindset.
Desired Qualifications
  • Experience in an accounting environment with significant exposure to revenue accounting being an advantage
  • Qualified/Part Qualified Accountant (ACA/ACCA/CIMA or equivalent) is an advantage
  • Knowledge and proficiency in US GAAP revenue accounting is an advantage
  • Work experience in a service driven function with a business partnering focus within a multinational shared service/GBS organization would be an advantage
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased focus on personalized medicine aligns with Vertex's patient-centric approach.

What critics are saying

  • Increased competition in cystic fibrosis could impact Vertex's market share.
  • Regulatory changes in the EU may delay Vertex's drug approvals.
  • High R&D costs and potential trial failures could strain Vertex's finances.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.